Latest news
Lexeo's PKP2 cardiomyopathy gene therapy adds RMAT status - AllSciAllSci · Thu, 06 Aug 2026 09:07:22 GMTLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 11:00:00 GMTLexeo's heart gene therapy gets FDA status after interim data - Stock TitanStock Titan · Wed, 05 Aug 2026 11:00:00 GMTLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For LX2020 For The Treatment Of PKP2 Arrhythmogenic Cardiomyopathy - marketscreener.commarketscreener.com · Wed, 05 Aug 2026 11:00:00 GMTLexeo wins FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy - BitgetBitget · Wed, 05 Aug 2026 03:39:36 GMTLexeo wins FDA RMAT status for LX2020 - PharmaTimesPharmaTimes · Mon, 03 Aug 2026 22:32:00 GMT